TP53 and breast carcinoma: PALB2 and TP53 also were associated with significant increases in breast cancer risk, with 11 patients and zero controls carrying a damaging mutation in PALB2 (P < .001), and four patients and zero controls carrying a damaging mutation in TP53 (P = .036).